etira
  • Home
  • Our Company
  • Our Science
  • Clinical Trial
  • Our Pipeline
  • Our Team
  • News
  • Publications
  • Contact
  • Menu Menu
  • LinkedIn
  • Home
  • Our Company
  • Our Science
  • Clinical Trial
  • Our Pipeline
  • Our Team
  • News
  • Publications
  • Contact

Publications

  • Cancer Research Communications 2026ERX-208 Induces Endoplasmic Reticulum Stress and Suppresses DNA Damage Repair to Enhance Chemotherapy Sensitivity
  • Biomolecules 2026Targeting LIPA with ERX-41 Induces ER Stress and Inhibits Tumor Progression in Inflammatory Breast Cancer
  • Oncogene 2026Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer
  • ACS Pharmacology & Translational Science 2024Structure–Activity Relationship Study of Tris-Benzamides as Estrogen Receptor Coregulator Binding Modulators
  • Methods in Enzymology 2024Oligo-benzamide-based peptide mimicking tools for modulating biology
  • Cancers 2024Novel LIPA-Targeted Therapy for Treating Ovarian Cancer
  • Nature Cancer 2022Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress
Nature Cancer cover, July 2022, Volume 3 Number 7: Targeting solid tumors by inducing ER stress

The founders’ breakthrough study, featured on the cover of Nature Cancer in 2022

 

etira logo

 

Where to find us

Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247

Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247

Scroll to top
Inclusion criteria:
  • Patients must be at least 18 years of age at the time of signing the informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
  • Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Adequate baseline organ function and hematologic function
  • Life expectancy >3 months
Exclusion criteria
  • Systemic anti-cancer therapy within 4 weeks of first dose of study drug
  • Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
  • Uncontrolled intercurrent illnesses
  • Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.